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Abstract
Evidence has been accumulating for an immune-based component to the etiology of psychotic 
disorders. Advancements in diffusion magnetic resonance imaging (MRI) have enabled estimation 
of extracellular free water (FW), a putative biomarker of neuroinflammation. Furthermore, 
inflammatory processes may be associated with altered brain levels of metabolites, such as 
glutathione (GSH). Consequently, we sought to test the hypotheses that FW is increased and 
associated with decreased GSH in patients with first episode schizophrenia (SZ) compared to 
healthy controls (HC). SZ (n=36) and HC (n=40) subjects underwent a multi-shell diffusion MRI 
scan on a Siemens 3T scanner. 1H-MR spectroscopy data were acquired using a GSH-optimized 
MEGA-PRESS editing sequence and GSH/creatine ratios were calculated for DLPFC (SZ: n=33, 
HC: n=37) and visual cortex (SZ: n=29, HC: n=35) voxels. Symptoms and functioning were 
measured using the SANS, SAPS, BPRS and GSF/GRF. SZ demonstrated significantly elevated 
FW in whole-brain gray (p=.001) but not white matter (p=.060). There was no significant 
difference between groups in GSH in either voxel. However, there was a significant negative 
correlation between DLPFC GSH and both whole-brain and DLPFC-specific gray matter FW in 
SZ (r=−.48 and −.47, respectively; both p<.05), while this relationship was nonsignificant in HC 
and in both groups in visual cortex. These data illustrate an important relationship between a 
metabolite known to be important for immune function – GSH – and the diffusion extracellular 
FW measure, which provides additional support for these measures as neuroinflammatory 
biomarkers that could potentially provide tractable treatment targets to guide pharmacological 
intervention.
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Introduction
Evidence has been accumulating for an immune-based component of schizophrenia (SZ) 
etiology. Mednick and colleagues 1 provided some of the first evidence many decades ago, 
identifying increased rates of psychotic disorders in the offspring of women who were 
exposed to infection while pregnant 2 see for review. In more recent years genetic links have 
been identified with the major histocompatibility complex, a section of the genome critical 
for immune function3. Furthermore, alterations in molecular markers mediating immune 
function, such as the cytokines IL-6, IFN-g, and TNF-a, have been repeatedly observed both 
in first episode and chronic individuals with schizophrenia, both on and off medication 4.
Recently, several groups have attempted to identify this “neuroinflammatory” signal using 
various brain imaging techniques. Initial studies using positron emission tomography and 
translocator protein (TSPO) ligands provided some evidence of increased microglial activity 
in gray matter and hippocampus 5, 6. However, more recent studies using second generation 
TSPO ligands, including some with larger samples, have not replicated this result 7–10.
Other putative markers of neuroinflammation may be measured using magnetic resonance 
imaging techniques, including diffusion imaging and proton spectroscopy. Pasternak and 
colleagues have recently demonstrated the utility of measuring extracellular free water, both 
as a method of adjusting for free water in the calculation of fractional anisotropy 11, but also 
as a separate biomarker that may be associated with inflammation or other 
neuropathological processes. This research group has demonstrated a pattern of increased 
free water and comparable white matter integrity in first episode psychosis samples 12, while 
a chronic sample showed more prominent reductions in fractional anisotropy 13. There is 
also preliminary evidence that chronically ill individuals with present state delusions show 
elevated free water compared to controls, particularly in the cingulum bundle, although free 
water did not distinguish those with present delusions from other patient groups with either 
past delusions or no lifetime history 14.
Furthermore, there is evidence that neuroimmune activation may alter brain levels of 
metabolites that can be measured non-invasively with proton magnetic resonance 
spectroscopy (1H-MRS). Glutathione (GSH) is a potentially informative inflammatory 
biomarker, as it is one of the major antioxidants in the human body and plays a role in cell 
proliferation, apoptosis, and immune function. GSH can be depleted by oxidative stress and 
is reduced in several neuroinflammatory conditions (e.g., multiple sclerosis, AIDS) 15, 16. In 
addition, recent mouse and in vitro studies have shown that GSH (directly and via its 
precursor, NAC) also has specific, protective interactions with neuroimmune response 
cascades, including inhibition of microglial activation and reduction of brain inflammatory 
markers evoked by neuroimmune activating agents 17, 18. One influential model that is 
supported by epidemiological studies as well as a large body of work using animal model 
systems posits that in some individuals, maternal immune activation, which may be related 
to maternal infections, exposures or other stressors in utero, causes a long-lasting 
sensitization of neuroimmune response elements in individuals who later develop 
schizophrenia. These sensitized systems might include the neuroimmune and 
proinflammatory functions of microglia and astrocytes. While GSH may not prevent this 
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initial sensitization, it could plausibly protect against some of the consequences of such 
sensitization. Sensitization renders the neuroimmune response elements vulnerable to 
activation by normally subthreshold provocations. GSH could inhibit such activation, as has 
been shown with its precursor, NAC, for microglial activation by LPS 17. Consequently, 
GSH is a strong candidate biomarker for psychotic disorders and the majority of studies 
have found GSH to be reduced in blood 19–35 and to some degree in CSF 29, 36 compared to 
control subjects. Useful measurement of GSH in brain with 1H-MRS requires either high 
field MR systems not generally available in clinical centers or advanced acquisition 
sequences, such as J-difference editing 37–39. In the earliest study of GSH in prefrontal 
cortex, Do and colleagues 36 used a double quantum coherence sequence at 1.5 Tesla and 
reported reduced medial prefrontal cortex (mPFC) GSH in 14 schizophrenia patients 
compared to 14 comparison subjects. However, more recent studies using a STEAM 
sequence at 4 Tesla 40 and a MEGA-PRESS editing sequence at 3 Tesla 41 observed no 
group differences in mPFC GSH. A study by Wood and colleagues 42 reported increased 
medial temporal cortex GSH in a psychotic disorder sample. However, the use of a 
conventional PRESS sequence at 3 Tesla makes it challenging to interpret these data 39. Of 
the four largest and most recent studies, two showed significantly lower GSH in patients 
compared to controls using a STEAM sequence at 7 Tesla 43, 44, while the other two studies 
showed no differences between patients and controls 19, 45 . It is not clear why GSH 
reductions have not been consistently observed. Small sample sizes, varying clinical features 
of the patient groups, and different technical methods may account for some of these 
differences.
The goal of the present study is to leverage the use of these two biomarkers, extracellular 
free water and cortical GSH, to further investigate the role of immune disruption in the brain 
in individuals with a first episode psychotic disorder. Given that free water may be 
influenced by a variety of factors, including inflammation, degeneration, or edema, testing 
the relationship to an established measure of immune function in brain—GSH—will inform 
the validity and clinical utility of this measure. Building upon previously published single-
shell diffusion studies in first episode psychosis 12 we used a multi-shell diffusion weighted 
acquisition optimized for the measurement of free water in brain tissue. We hypothesize that 
free water will be increased in individuals with first episode psychosis. We also predict that 
dorsolateral prefrontal cortex (DLPFC) GSH level will correlate negatively with free water 
in patients, reflecting a convergence of factors associated with neuroinflammation that varies 
in degree among individuals with first episode psychosis. In addition, we will test the 
hypothesis that GSH is reduced in the patient group as a whole.
Methods and Participants
Thirty-nine first episode schizophrenia patients (See Table 1 for diagnoses and clinical 
status) and 41 control subjects between the ages of 16 and 30 were recruited for the study. 
After exclusions for data quality, 36 schizophrenia and 40 control participants remained with 
good diffusion data. Of this sample, 33 patients and 37 controls had good quality DLPFC 
GSH data and 29 patients and 35 controls had good visual cortex GSH data (see 
Supplementary Information for details). Participants with schizophrenia-spectrum diagnoses 
were outpatients within two years of their first psychotic episode. All participants were 
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assessed using the Structured Clinical Interview for the DSM-IV-TR SCID-I/P; 46. Clinical 
ratings were collected in the patient group using the Scale for the Assessment of Negative 
Symptoms SANS; 47, Scale for the Assessment of Positive Symptoms SAPS; 48, Brief 
Psychiatric Rating Scale BPRS; 49, and Global Functioning: Social 50 and Role 51 scales. 
Exclusion criteria for both groups included: Wechsler Abbreviated Scale of Intelligence 
(WASI) IQ score below 70, alcohol or drug dependence or abuse within 3 months before 
testing, positive urine toxicology screen for illicit drugs, prior head trauma worse than a 
Grade I concussion, or contraindication to MRI scanning. Control subjects were excluded 
for the following additional criteria: any lifetime diagnosis of an Axis I or Axis II disorder or 
any first-degree relatives with a psychotic disorder. Before testing, a detailed description of 
the study was provided and written informed consent obtained. The study was approved by 
the University of California, Davis Institutional Review Board and all subjects consented to 
and were paid for their participation.
Imaging Parameters and Data Analysis
Imaging data were obtained using a 3T Siemens Tim Trio MRI scanner. T1-weighted 
MPRAGE structural images were acquired with the following settings: TR=2,530-msec, 
echo time=3.5-msec, flip-angle=7˚, field of view=256mm, 1mm isotropic voxels. 1H-MRS 
data were acquired from voxels placed in the DLPFC and in the visual cortex, as a control 
region (see Supplementary Information). GSH was measured with a MEGA-PRESS, J-
difference, editing sequence optimally adapted for GSH 37, 52–54. Parameters included: 
TE/TR = 131/2000; bandwidth = 2000 Hz; on and off resonance SLR edit pulse frequencies 
= 4.56 and 4.90 ppm; edit pulse bandwidth = 30 Hz; edit pulse duration = 39.68 msec. The 
edited spectra were acquired in two sequential acquisitions of 176 averages each (total 352 
averages, 11.7 minutes total duration). A conventional PRESS sequence was acquired from 
the same voxels with TE/TR = 30/1500 and 160 averages.
The diffusion sequence was acquired with the following settings: TR=11,400-msec, echo 
time=92.4-msec, field of view=240mm, 1.7mm isotropic voxels. The sequence included 56 
directions acquired P-A with the following b-shells: 12 x b=0, 10 x b=500, 30 x b=900, 16 x 
b=1400. Diffusion images were first visually inspected for image quality and images 
containing artifacts were discarded. The remaining diffusion weighted images underwent 
eddy current correction and realignment using FSL’s eddy 55, including rotation of b-
matrices. The Dipy diffusion imaging library 56 and included free water elimination model 
57
 were used to calculate all diffusion metrics. This model expands the typical DTI model 
and assumes that each voxel contains two components: an anisotropic tissue-bound 
component and an isotropic extracellular free water component. In this study, we evaluated 
both the free water component and tissue-specific fractional anisotropy (FA-t), which 
reflects traditional FA with the free water component eliminated.
In order to calculate free water values specific to gray and white matter, brain extraction and 
segmentation of MPRAGE images was performed using Freesurfer 5.3 58. White and gray 
matter masks from Freesurfer were brought into alignment with each subject’s free water 
image using bbregister 59. Each MPRAGE underwent a rigorous quality inspection by 
individuals blind to group—including talairach alignment evaluation, meninges/skull 
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removal, white matter editing, and surface inspection, according to standard Freesurfer 
documentation. Mean free water values were calculated across all voxels within gray and 
white matter masks for each subject.
To further explore the regional specificity of gray and white matter free water, two additional 
analyses were performed (see Supplement). Briefly, free water maps were projected onto 
individual subject cortical surfaces using Freesurfer’s mri_vol2surf to assess free water in a 
vertex-wise manner using mri_glmfit. Multiple comparisons correction was employed using 
cluster analysis with Freesurfer’s precomputed Z Monte Carlo simulation (cluster threshold 
of p<0.01 and clusterwise probability of p<0.05). White-matter free water and FA-t maps 
were nonlinearly aligned to the FMRIB58_FA image using FNIRT and projected on the 
white matter skeleton using FSL’s Tract Based Spatial Statistics (TBSS) 60. Randomise61 
and threshold-free cluster enhancement62 were used to define clusters and correct for 
multiple comparisons.
GSH was quantified by peak integration of the MEGA-PRESS difference spectra using 
LCModel 6.3–1L 63, jMRUI 5.2 64 and custom software in an operator-independent 
sequence of processing steps. The on and off resonance spectra from each acquisition were 
first zero-filled (2x), phase-aligned, and apodized in jMRUI. The on and off resonance 
spectra were then frequency-aligned using custom software and subtracted to generate 
difference spectra. The two difference spectra were phase and frequency aligned to each 
other and summed. The GSH cysteine resonance at 2.95 ppm was then quantified by line-
width optimized peak integration in the final difference spectrum. The creatine resonance at 
3.02 ppm was similarly quantified by peak integration in the final summed spectrum and 
used to calculate the GSH/creatine ratio (Supplementary Figure 1). To explore the specificity 
of the correlation between free water and GSH, five supplementary metabolites (total 
choline, total NAA, total creatine, glutamate, and inositol) from the PRESS acquisition were 
tested for relationships with whole-brain gray/white free water values (see Supplement).
Statistical Methods
Differences in demographic characteristics were assessed with Pearson Chi-Square or 
independent samples t-tests, where appropriate. Between-group free water and GSH/creatine 
ratios were assessed with independent samples t-tests and relationships between free water 
and GSH/creatine ratios were tested with Pearson r correlations. Any measures that were not 
normally distributed underwent follow-up non-parametric tests and are reported if 
significance changed. Alpha was set at p<.05, two-tailed, to determine significance for all 
tests.
Results
Participant demographic and clinical information is presented in Table 1. The groups did not 
differ significantly on age (t(74)=.70, p=.48), gender (χ2=.033, p=.86), or parental education 
(t(71)=.42, p=.67). Controls were more highly educated than patients (t(74)=3.37, p=.001) 
and showed significantly higher estimated IQ (t(71)=3.05, p=.003).
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Between-group Comparisons
As seen in Figure 1, individuals with first episode schizophrenia demonstrated significantly 
elevated free water in whole-brain gray (t(74)=3.79, p<.001) with a trend elevation in white 
matter (t(74)=1.91, p=.060). There were no significant group differences in GSH within the 
DLPFC (t(68)= 1.07, p=.29) or visual cortex voxels (t(62)=.19, p=.85). There was a 
significant negative correlation (Figure 2) between DLPFC GSH and gray matter free water 
in the patient group (r=−.48, p=.004), although the relationship with white matter free water 
did not reach significance (r=−.26, p=.14). Free water was not correlated to GSH in controls 
or any visual cortex data. Finally, the relationship between DLPFC GSH and gray matter 
free water was significantly stronger in first episode participants compared to controls 
(Fisher’s r-to-z, p=.005). The strength of the free water-GSH relationship did not differ 
between groups in the other three comparisons (all p>.32).
A follow-up analysis was also performed on free water in tissue specifically restricted to the 
MRS voxel location and detailed in the Supplement. In brief, these results are very similar to 
the whole-brain findings, with a significant relationship in patients between DLPFC voxel-
specific gray matter free water and DLPFC GSH (r=−.472, p=.006), with a significantly 
stronger relationship in patients compared to controls (Fisher’s r-to-z, p=.02).
Voxel-wise TBSS analyses revealed significantly increased free water in patients with 
schizophrenia compared to controls (Figure 3) across both hemispheres in a relatively 
widespread pattern. No group differences were identified in the voxel-wise FA-t TBSS 
analysis.
Vertex-wise analyses of gray matter free water projected to the cortical surface revealed 
significantly increased free water in patients with schizophrenia in lateral frontal cortex, 
right rostral anterior cingulate, bilateral temporal cortex extending into the insula, left 
hemisphere inferior parietal cortex, left hemisphere posterior cingulate, and occipital cortex 
(Figure 4 and Supplementary Table 1).
Specificity of GSH-Free Water Relationship
Potential concerns in testing only the relationship between GSH and free water are that the 
association could potentially be driven by creatine-associated variance in the GSH/Cr ratio 
or that the GSH-free water association is not specific to GSH. For example, inositol has also 
been linked to neuroimmune alterations 65–67. To explore these issues, we evaluated the 
relationship between free water and the other reliably estimated creatine normalized 
metabolites (total choline, NAA, glutamate, inositol, and the absolute value of creatine; all 
CRLB < 10%) from the DLPFC PRESS acquisition. None of these metabolites significantly 
correlated with gray or white matter free water in either group (all p > .13), suggesting a 
specific relationship with GSH.
Relationships to Symptoms and Functioning
Clinical scores were included in vertex- and voxel-wise whole-brain regressions with free 
water using Freesurfer and TBSS. Significant positive associations were identified between 
prefrontal gray matter free water (rostral middle frontal gyrus and anterior cingulate) and 
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both SAPS and BPRS total scores (Supplementary Figure 3 and Supplementary Table 2). No 
voxels survived correction for multiple comparisons in white matter free water-symptom 
analyses.
Discussion
These data represent the first evaluation of both GSH and multi-shell diffusion extracellular 
free water in a first episode schizophrenia sample. In agreement with results reported by 
Pasternak et al. 12, free water was elevated in individuals with first episode psychosis in both 
white and gray matter. Furthermore, while the groups did not differ on GSH, the significant 
inverse relationship observed between GSH and gray matter free water could reflect a 
common linkage to neuroinflammatory processes. Consistent with most prior studies, 
prefrontal GSH levels were not different between psychosis and control groups. While free 
water could represent an amalgam of biological processes, including inflammation, 
degeneration, or edema, the significant relationship to a known inflammation-related 
metabolite, GSH, provides additional support for the link between free water and 
neuroimmune processes and the use of the combination of measures as complementary 
biomarkers to guide pharmacological intervention.
Several studies using single-shell diffusion data have shown that extracellular brain free 
water is increased in patients with first episode schizophrenia 12, 68 and, to a lesser degree, 
chronic schizophrenia 13, 69. We show similar increases in free water throughout the white 
matter skeleton using an optimized multi-shell sequence, which should represent an 
improvement in estimating free water. Furthermore, we used the novel approach of 
evaluating gray matter free water projected on the cortical surface, which identified lateral 
and medial prefrontal, temporal/insula, inferior parietal, and occipital clusters of increased 
free water in the schizophrenia sample. These specific regions of elevated free water notably 
overlap with regional disruptions of gray matter density 70, 71, cortical thickness 72, 73, and 
fMRI BOLD 74 activity that are repeatedly identified in individuals with schizophrenia. 
Notably, we also found that higher free water in prefrontal gray matter was also associated 
with worse symptomatology, suggesting that this measure may index clinical severity.
Although free water was the primary diffusion metric for the present study, we also 
investigated FA-t in order to evaluate microstructural white matter integrity between groups. 
Our analyses revealed no significant differences in FA-t throughout the white matter 
skeleton. While the majority of published studies suggest decreases in fractional anisotropy 
75–77
 only more recent studies have applied the free water elimination model to evaluate FA-
t. This is critically important, given that free water contamination of voxels may artificially 
lower traditional FA values in individuals who have more free water. Specifically, the studies 
that evaluated FA-t in first episode samples identified relatively isolated FA-t decreases 12, 68 
in contrast to the more widespread traditional FA decreases in chronic schizophrenia. The 
young, first episode sample in the present study, with a short duration of illness, treated with 
relatively low doses of antipsychotics, and an absence of substance abuse may also partially 
explain the lack of FA-t differences.
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Our finding of similar levels of GSH in patient and control groups is relatively consistent 
with the GSH literature, given that the majority of published studies have also shown no 
significant differences 19, 40, 41, 45. Since the pioneering work of Do and colleagues 36, there 
have been only two additional published reports of lowered brain GSH in schizophrenia 
43, 44
, although a negative relationship between GSH levels and negative symptoms has been 
reported 41.
Interestingly, the relationship between GSH and free water was only identified in individuals 
with first episode psychosis and only in the DLPFC voxel. In addition, the specific 
relationship between DLPFC GSH and gray matter free water was significantly stronger in 
the patient group compared to controls. One interpretation of these findings is that this 
relationship may emerge only in the presence of an inflammatory process. Additionally, the 
lack of any relationships between free water and the visual cortex control region suggests 
that there may be some regional specificity to these findings, and add to the large body of 
existing literature demonstrating DLPFC dysfunction across many imaging modalities in 
first episode schizophrenia. Several interacting homeostatic mechanisms regulate brain 
tissue GSH levels, tending to keep them within a range of normal values 78, 79. Some 
inflammatory processes can alter this process sufficiently to cause low GSH levels, such as 
in multiple sclerosis 80, 81. Some inflammatory processes do not have this effect, and GSH 
levels remain normal, as in ALS, for example 82, 83. It is possible that an inflammation-
related process in schizophrenia could cause elevated free water without causing reduced 
GSH at the mean group level, as is suggested by our data. In this case, GSH could be serving 
a protective function. Those patients who maintain a relatively high GSH level may benefit 
from greater protection against inflammation compared to those patients who maintain a 
relatively low GSH level. In the absence of an underlying inflammatory process in the 
control group, GSH levels are not expected to correlate inversely with free water values in 
this group. This is because GSH is not serving a protective role against a pathogenic process 
causing elevated free water in this group.
Limitations
GSH is a difficult metabolite to measure, particularly at lower field strengths. Our approach 
was to use an optimized MEGA-PRESS sequence at 3 Tesla and to quantify GSH relative to 
creatine. It is possible that more sensitive measures of GSH or larger sample sizes might 
have revealed further associations with GSH levels. There have been reports in the literature 
that creatine levels may be reduced in schizophrenia 84, although a recent meta-analysis 
found no evidence for decreased creatine in schizophrenia or bipolar disorder 85. Lower 
creatine levels in the patient group would tend to skew results in the opposite direction of 
our hypotheses, with the patient group potentially showing a bias towards a higher GSH/
creatine ratio. Given that our findings reveal no significant differences between groups, it 
remains possible, although unlikely, that differences in creatine may have contributed to the 
null result. However, an exploratory evaluation of other metabolites normalized to creatine 
revealed a specific relationship with the GSH/creatine ratio and free water, which suggests 
creatine is not the main driver of these findings. An additional concern is that 
neuroinflammation is only one possible mechanism that could account for the pattern of 
findings we report here. For instance, increases in free water could reflect other 
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neuropathological processes unrelated to immune processes, although the lack of group 
differences in FA-t suggests that free water increases are not likely due to white matter 
degradation. An additional concern is that the majority of subjects in the sample were taking 
antipsychotic medication and a growing body of literature suggests that antipsychotics may 
have anti-inflammatory properties. Recent meta-analyses of the cytokine literature 4, 86 
highlight antipsychotic-related decreases of pro-inflammatory cytokines in the peripheral 
circulation, particularly IL-1B, IL-6, and IFN-g. Additionally, antipsychotics have been 
associated with inhibition of these same pro-inflammatory cytokines in stimulated microglia 
cultures 87. Additional work, particularly in animal models and antipsychotic-naïve 
individuals, is needed to investigate these relationships.
Conclusions and Future Directions
These data provide compelling evidence that the simultaneous acquisition of different 
imaging measures including extracellular free water and GSH can inform our understanding 
of altered neuroinflammatory processes that may underlie the developmental biology of 
psychotic disorders. However, the overlap between control and patient groups in both free 
water and GSH values is considerable and consequently only a subset of patients may 
evidence a strong immune component to the etiology of their illness. Indeed, post mortem 
analyses in schizophrenia have suggested that there is increased expression of inflammation-
related genes in perhaps thirty 88 to forty 89 percent of patients. This heterogeneity may 
partly explain why several clinical trials evaluating add-on treatment using anti-
inflammatory agents have shown relatively modest benefits in relieving symptomatology 
90–95
, with one additional study showing no benefit 96. Consequently, the use of MRI-based 
markers such as those used in the present study may offer the potential of a more 
personalized approach to clinical trials of inflammation-related therapies, in which patients 
are stratified based upon diffusion MRI data and offered targeted intervention based upon 
these measures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Whole-brain gray and white matter free water values. Independent samples t-test revealed 
increased free water in first episode schizophrenia patients (SZ) compared to controls (HC) 
in gray matter (p<.001), with a trend elevation in white matter (p=.060). Black lines 
represent the mean. Means and standard deviations are presented in Supplementary Table 3.
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Figure 2: 
Relationships between glutathione (GSH) and free water measures were tested with Pearson 
r correlations. The top two panels present the relationship between gray (top left) and white 
(top right) free water and DLPFC GSH values. The bottom two panels present the 
relationship between gray (bottom left) and white (bottom right) free water and visual cortex 
GSH values. A significant inverse relationship was identified between GSH in the 
hypothesized DLPFC region and gray matter free water in schizophrenia patients (p=0.004). 
Additionally, the relationship between GSH and gray matter free water was stronger in the 
schizophrenia group compared to the control group (Fisher’s r-to-z, p=.005).
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Figure 3: 
Tract-based spatial statistics voxel-wise analysis of free water group differences presented in 
axial slices. Regions in red depict areas in which first episode schizophrenia patients showed 
significantly higher free water compared to controls. Clusters presented survive correction 
for multiple comparisons (p<.05).
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Figure 4: 
Representation of regional group differences in free water in the cortical gray matter. Free 
water was projected on the cortical surface and tested for group differences using Freesurfer 
tools. Hot colors represent clusters in which first episode schizophrenia patients (SZ) show 
significantly higher free water compared to controls (HC) in the left (LH) and right (RH) 
hemispheres. Clusters presented survive correction for multiple comparisons (p<.05). The 
color scale ranges from 2 to 5, representing −log10(p-value) of p=.01 to .00001.
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Table 1:
Sample demographic and clinical characteristics.
Control (n=40) Schizophrenia (n=36)
Age: mean (SD) 21.9 (2.8) 21.4 (3.4)
Gender: number Male/Female 27 / 13 25 / 11
Education: mean (SD) 14.3 (2.6) 12.5 (1.9)*
Parental Education: mean (SD) 14.7 (3.5) 14.4 (2.9)
WASI: mean (SD) 115.8 (12.3) 104.6 (18.6)*
Diagnosis: (n)
 Schizophreniform - 3
 Schizophrenia - 18
 Schizoaffective - 15
Antipsychotic Dose: mean CPZ equivalent (SD) - 226.64 (168.7)
SANS - 11.2 (3.6)
SAPS - 4.4 (3.4)
BPRS - 46.8 (12.0)
Global Functioning: Social - 6.1 (1.5)
Global Functioning: Role - 3.5 (2.5)
SD: Standard Deviation; WASI: Wechsler Abbreviated Scale of Intelligence; CPZ: chlorpromazine; SANS: Scale for the Assessment of Negative 
Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; BPRS: Brief Psychiatric Rating Scale.
*p<.05.
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